诺唯赞：啃下国产生物试剂“硬骨头”

Core Insights - The article highlights the rise of domestic biological reagents in China, which have historically relied on imports, as the industry undergoes significant transformation due to the growth of the pharmaceutical and health sectors [1][2] - Nanjing Novozan Biotechnology Co., Ltd. has established a self-controlled technology platform, overcoming key technical challenges in high-end enzymes and antibodies, thereby enhancing China's biopharmaceutical supply chain [1][2][3] Industry Overview - Biological reagents, including enzymes and antibodies, are essential for research and development in life sciences, diagnostics, and vaccine production, often referred to as the "chip" of life sciences [1] - The industry has seen a shift as domestic companies like Novozan gain ground against foreign competitors, particularly in high-end reagent markets [1][2] Company Development - Founded in 2012, Novozan began its journey to develop localized biological reagents, addressing issues such as high costs and long delivery times associated with imported products [2][3] - The company has achieved significant breakthroughs in key technologies, enabling it to produce a range of over 1,000 types of recombinant enzymes and 3,000 types of high-performance antigens and monoclonal antibodies [5][6] Product Innovation - Novozan successfully developed a domestic high-sensitivity troponin test for early diagnosis of myocardial infarction, which is priced at 60% of the imported equivalent and delivers results in just 8 minutes [3][4] - The company is focusing on Alzheimer's disease (AD) blood testing, with products already in use in over 100 top-tier hospitals and third-party testing institutions [5][6] Marketing Strategy - Novozan's marketing approach for AD testing emphasizes a comprehensive service ecosystem that integrates technology development, clinical application, and academic outreach, rather than just product sales [6][7] - The company aims to enhance public awareness of AD and provide tailored solutions to medical institutions, establishing strategic partnerships to create a complete diagnostic and treatment ecosystem [6][7] International Expansion - Novozan has begun exporting products, including NGS (Next Generation Sequencing) reagents, to international markets, marking a significant step in its global strategy [8][9] - The company has established warehouses in key regions such as North America, Europe, and Southeast Asia to improve delivery times, reducing the product delivery cycle from 40-50 days to as little as 3 days [10]